The benefit of hormone replacement therapy on bone mass is greater at the vertebral body than posterior processes or proximal femur
- PMID: 9356739
- DOI: 10.1016/s8756-3282(97)00177-4
The benefit of hormone replacement therapy on bone mass is greater at the vertebral body than posterior processes or proximal femur
Abstract
The aim of this study was to determine whether the higher vertebral bone mass in women receiving hormone replacement therapy (HRT) is confined to the trabecular rich vertebral body rather than the predominantly cortical posterior processes, and to determine whether the protective effect of HRT at the proximal femur, a predominantly cortical site, is less than at the spine. Bone mass (g) of the third lumbar vertebra (total, vertebral body and posterior processes, measured by lateral scanning), and bone mineral density (g/cm2) of the femoral neck, Ward's triangle, and trochanter were measured using dual X-ray absorptiometry in a cross-sectional study of 71 women receiving HRT for 5.7 +/- 0.4 years (mean +/- SEM), ranging from 1 to 21 years, 69 age-matched controls, and 42 premenopausal controls aged 20 to 40 years. Relative to untreated postmenopausal controls, total bone mass of the third lumbar vertebra (body plus posterior processes) by postero-anterior (PA) scanning was 0.4 +/- 0.1 SD or 9.6 +/- 3.0% higher in HRT treated women (p < 0.01). By lateral scanning, total bone mass was higher than age-matched controls (z score 0.4 +/- 0.1 SD or 11.2 +/- 3.4%, p < 0.01). This difference was confined to the vertebral body (z score 0.6 +/- 0.1 SD, p < 0.001), which was 17.1 +/- 3.3% higher than in age-matched controls (p < 0.001). Bone mass of the posterior processes was no higher [z score 0.1 +/- 0.1, not significant (NS)]. The deficit at the vertebral body in HRT-treated women, relative to premenopausal controls, was half the deficit at the vertebral body in untreated postmenopausal women (t score -0.7 +/- 0.1 vs. -1.4 +/- 0.1 SD, respectively; p < 0.001) but no less at the posterior processes (t score -1.6 +/- 0.2 vs. -1.9 +/- 0.2 SD, respectively; NS). Similarly, the deficit in the vertebral body in the HRT treated group was half the deficit at their posterior processes (t score -0.7 +/- 0.1 SD vs. -1.6 +/- 0.2, respectively; p < 0.001). In HRT-treated women, bone mass diminished significantly with age at the posterior processes (r = -0.31, p < 0.01), but not at the vertebral body (r = -0.21, p = 0.07). Bone mass diminished significantly with age at the vertebral body and posterior processes in untreated women (r = -0.55, p < 0.001; r = -0.45, p < 0.001, respectively). Bone density (g/cm2) diminished at all femoral sites with advancing age in HRT-treated women. A protective effect was seen at the femoral neck and Ward's triangle, but not trochanter (z score 0.2 +/- 0.1, p = 0.06; 0.3 +/- 0.1, p < 0.05; 0.0 +/- 0.1, NS, respectively). In conclusion, the protective effect of HRT against bone loss at the vertebral body, the site of fracture in osteoporosis, may be underestimated by PA scanning. The greater benefit at the vertebral body, and more modest effect at the proximal femur, suggests that HRT may be a more effective means of reducing the risk of spine than hip fractures.
Similar articles
-
Parathyroid hormone deficiency and excess: similar effects on trabecular bone but differing effects on cortical bone.J Clin Endocrinol Metab. 1999 Feb;84(2):718-22. doi: 10.1210/jcem.84.2.5498. J Clin Endocrinol Metab. 1999. PMID: 10022443
-
Equivalent deficits in bone mass of the vertebral body and posterior processes in women with vertebral fractures: implications regarding the pathogenesis of spinal osteoporosis.J Bone Miner Res. 1995 Dec;10(12):2005-10. doi: 10.1002/jbmr.5650101221. J Bone Miner Res. 1995. PMID: 8619382
-
Effects on bone mass after eight years of hormonal replacement therapy.Br J Obstet Gynaecol. 1997 Jun;104(6):702-7. doi: 10.1111/j.1471-0528.1997.tb11981.x. Br J Obstet Gynaecol. 1997. PMID: 9197874 Clinical Trial.
-
[Hormone replacement and selective estrogen receptor modulators (SERMS) in the prevention and treatment of postmenopausal osteoporosis].Orthopade. 2001 Jul;30(7):462-72. doi: 10.1007/s001320170079. Orthopade. 2001. PMID: 11515185 Review. German.
-
European and North American Experience with HRT for the prevention of osteoporosis.Bone. 1996 Nov;19(5 Suppl):179S-183S. doi: 10.1016/s8756-3282(96)90162-3. Bone. 1996. PMID: 8922659 Review.
Cited by
-
Bone Matrix Levels of Dickkopf and Sclerostin are Positively Correlated with Bone Mass and Strength in Postmenopausal Osteoporosis.Int J Mol Sci. 2019 Jun 14;20(12):2896. doi: 10.3390/ijms20122896. Int J Mol Sci. 2019. PMID: 31197079 Free PMC article.
-
Evaluation of new bone formation in normal and osteoporotic rats with a 3-mm femur defect: functional assessment with dynamic PET-CT (dPET-CT) using 2-deoxy-2-[(18)F]fluoro-D-glucose ( (18)F-FDG) and (18)F-fluoride.Mol Imaging Biol. 2013 Jun;15(3):336-44. doi: 10.1007/s11307-012-0592-9. Mol Imaging Biol. 2013. PMID: 22965489
-
Differential effects of hormone replacement therapy on bone mineral density and axial transmission ultrasound measurements in cortical bone.Osteoporos Int. 2003 Jun;14(4):289-94. doi: 10.1007/s00198-002-1353-4. Epub 2003 Apr 15. Osteoporos Int. 2003. PMID: 12730793 Clinical Trial.
-
The 18 kDa translocator protein (peripheral benzodiazepine receptor) expression in the bone of normal, osteoprotegerin or low calcium diet treated mice.PLoS One. 2012;7(1):e30623. doi: 10.1371/journal.pone.0030623. Epub 2012 Jan 25. PLoS One. 2012. PMID: 22295097 Free PMC article.
-
PLCL1 rs7595412 variation is not associated with hip bone size variation in postmenopausal Danish women.BMC Med Genet. 2009 Dec 23;10:145. doi: 10.1186/1471-2350-10-145. BMC Med Genet. 2009. PMID: 20030815 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous